FET-PET/MRI Based Treatment Planning for Glioblastoma Multiforme in Post-Surgical Patients (FET-TREAT)

FET-PET/MRI Based Treatment Planning for Glioblastoma Multiforme in Post-Surgical Patients (FET-TREAT)

Glioblastoma multiforme (GBM) represent the most common primary brain malignancy and prognosis remains poor. The most common subtype is glioblastoma which has a 5-year survival rate of approximately 5%. Despite advances in MRI techniques, accurately determining total extent of tumor remains a challenge. The result is incomplete treatment resulting in reduced survival or overtreatment resulting in avoidable treatment related morbidity. A more accurate means of assessing tumor extent is needed to guide management to improve patient survival and quality of life.

Inclusion Criteria:

Each participant must meet all of the following inclusion criteria to participate in this study:

• ≥ 18 years of age
• Diagnosis of glioblastoma multiforme
• Post-maximally safe surgical resection
• No prior radiation or systemic treatment for high grade glioma
• Able to tolerate PET/MRI scan with intravenous contrast
• Willing to provide informed consent

Exclusion Criteria:

All participants meeting any of the following exclusion criteria at baseline screening will be excluded from participation in this study:

• MRI contraindication
• Creatinine clearance < 30mL/min
• Inability to lie still for 60 minutes
• Gadolinium allergy
• Positive pregnancy test
• Breastfeeding
• Patient unable to follow the protocol for any reason